☆ 4.5 Article

PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment

ACS MEDICINAL CHEMISTRY LETTERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article Pharmacology & Pharmacy

Therapeutic advancements in targeting BCL-2 family proteins by epigenetic regulators, natural, and synthetic agents in cancer

Arnab Sarkar et al.

Summary: Cancer is a highly lethal and disruptive disease with a rising global death rate. Understanding the role of apoptosis in cancer and targeting BCL-2 family proteins is crucial for developing and managing this disorder. This review discusses the use of various epigenetic regulators, including miRNAs and lncRNAs, to target BCL-2 family proteins. Additionally, the study highlights the advancements in natural and synthetic molecules to understand and treat neoplastic diseases through transcriptional alterations and the development of inhibitors and activators of apoptotic proteins.

EUROPEAN JOURNAL OF PHARMACOLOGY (2023)

添加到收藏夹
Review Hematology

Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?

Prajwal Dhakal et al.

Summary: Venetoclax is a highly selective BCL-2 inhibitor that shows initial response in AML patients, but relapse is common. Resistance mechanisms include TP53 mutations, activating kinase mutations, and upregulation of other apoptotic proteins. Clinical trials are exploring strategies to overcome resistance and improve outcomes using combination therapies and immunotherapeutic approaches.

BLOOD REVIEWS (2023)

添加到收藏夹
Review Biochemistry & Molecular Biology

Clinical considerations for the design of PROTACs in cancer

Cristina Nieto-Jimenez et al.

Summary: The development of protein degradation drugs (PROTACs) is of great importance in cancer treatment. By selecting the appropriate proteins as degradation targets and ubiquitin ligases that are highly expressed in tumor cells but not in normal tissues, the efficacy of treatment can be enhanced while minimizing toxicity.

MOLECULAR CANCER (2022)

添加到收藏夹
Review Chemistry, Medicinal

Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins

Pratik Pal et al.

Summary: The BCL-2 family proteins, including BCL-2, BCL-XL, and MCL-1, are important targets for cancer therapy. In recent years, there have been significant advancements in developing inhibitors and PROTACs for these proteins. FDA approval of venetoclax, a BCL-2 selective inhibitor, has paved the way for further research and development. Efforts are being made to improve drug properties and overcome toxicity issues associated with MCL-1 and BCL-XL inhibitors. Technologies like ADC and PROTAC show promise in increasing the therapeutic index of MCL-1 inhibitors.

EXPERT OPINION ON THERAPEUTIC PATENTS (2022)

添加到收藏夹
Review Oncology

Targeting MCL-1 in cancer: current status and perspectives

Haolan Wang et al.

Summary: MCL-1, an antiapoptotic protein, is frequently overexpressed in many tumor types and closely associated with tumorigenesis, poor prognosis, and drug resistance. Its central role in regulating the mitochondrial apoptotic pathway makes it an attractive target for cancer therapy. Progress has been made towards MCL-1 inhibitors and some have entered clinical trials.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹
Review Chemistry, Medicinal

PROTAC: A promising technology for cancer treatment

Xin Zhou et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)

添加到收藏夹
研讨会 海报 问题 讨论圈 基金 期刊 论文 科研社交 资讯集成 审稿人 关于我们 常见问题 移动App 隐私条款 使用条款
© Peeref 2019-2024. All rights reserved.